The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders
- 124 Downloads
Aims of the study
To assess the impact of olanzapine versus conventional neuroleptic therapy among subjects with schizophrenia on ratings of tardive dyskinesia (TD).
The naturalistic study was conducted in three psychiatric hospitals in Brazil. Patients had a diagnosis of schizophrenia and related disorders (DSMIV) and with a BPRS score > 24. Patients were evaluated by means of the PANSS scale for symptomatology (Kay et al. 1986), the Clinical Global Impression, The UKU side effect rating scale (Lingjaerde et al. 1987), and the Tardive Dyskinesia AIMS scale (Guy et al. 1976). Patients were seen by the treating physician routinely while hospitalized and then monthly on an out-patient basis. All scale assessments were repeated after 9 months of discharge.
The sample was comprised of 190 patients (99 in the olanzapine and 91 in the standard treatment), with a completion rate of 88.2 % for olanzapine and 84.9% for the conventional treatment (p=0.385, n. s.). The mean change from baseline in the PANSS total score favored olanzapine regarding negative symptoms (2.3, 95% C. I. 0.6–4.1, p < 0.001); and general psychopathology (4.0, 95% C.I. 0.8–7.2, p < 0.02) factors. TD was defined by applying Morgenstern & Glazer (1993) and Schooler & Kane (1982) criteria, on the basis of the AIMS scale. Both results favored olanzapine at the end of the follow-up (Morgenstern & Glazer: 25.6% versus 56.3%; Schooler & Kane: 16.3% versus 45.2 %). At the end of the follow-up, by using the overall rating of the AIMS scale, the presence of TD was 2.3% for olanzapine (2/87), and 16.7% (12/72) for the conventional treatment.
The results of this open label naturalistic trial showed that olanzapine had an impact on negative symptoms, decreased general psychopathology and reduced the risk of tardive dyskinesia.
Key wordsschizophrenia tardive dyskinesia randomized controlled trial olanzapine typical antipsychotic
Unable to display preview. Download preview PDF.
- 1.Beasley CM, Hamilton S, Crawford AM, et al. (1997) Olanzapine versus Haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 7:125–137Google Scholar
- 4.Duggan L, Fenton M, Dardennes RM, et al. (2003) Olanzapine for schizophrenia. Cochrane Database Syst Rev (1):CD001359Google Scholar
- 6.Glazer WM (2000) Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 61(Suppl 4):15–20Google Scholar
- 7.Guy W (1976) Psychopharmacology Research Branch, NIMH. Abnormal Involuntary Scale (AIMS). In: ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Pub. No (ADM) 76–338. Rockville, MD: National Institute of Mental Health, pp 534–537Google Scholar
- 11.Kay SR, Opler LA, Fizbein A (1986) Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, New York, Multi Health Systems, IncGoogle Scholar
- 12.Leitão R, Ferraz MB, Mari JJ (2002) A prevalence based cost of illness study of schizophrenia in São Paulo State, Brazil. Schizophr Res 53(Suppl 3):259Google Scholar
- 13.Lingjaerde O, Ahlfors UG, Bech P, et al. (1987) The UKU side effect rating scale. Acta Psychiatr Scand 76(Suppl 334):1–100Google Scholar
- 15.Loza N, El-Dosoky AM, Okasha TA, et al. (1999) Olanzapine compared to chlorpromazine in acute schizophrenia. Eur Neuropsychopharmacol 9(Suppl 5):291Google Scholar
- 16.Mitchell IJ, Cooper AC, Griffiths MR, et al. (2002) Acute administration of haloperidol induces apoptosis of neuron in the striatum and substantia nigra in the rat. Neuroscience 109(1):89–99Google Scholar
- 18.Schooler NR, Kane JM (1982) Research diagnoses for tardive dyskinesia (letter). Arch Gen Psychiatry 39:486–487Google Scholar
- 21.Tollefson GD, Beasley CM, Tran PV, et al. (1997a) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154(4):457–465 Google Scholar
- 22.Tollefson GD, Beasley CM, Tamura RN et al. (1997b) Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 154(9):1248–1254 Google Scholar